Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 5Tumor-Agnostic 3Head & Neck 2Genitourinary 2Sarcoma 1NET 1Endocrine 1

Conditions

Squamous Cell Carcinoma of Head and Neck 20Head and Neck Neoplasms 12Nasopharyngeal Carcinoma 10Sarcoma 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Mesothelioma 2Melanoma 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Testicular Germ Cell Tumor 1Recurrence 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 35Cetuximab 18Gemcitabine 14Nivolumab 13Cisplatin 13Paclitaxel 10Carboplatin 9Cyclophosphamide 7cemiplimab 6Fluorouracil 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Docetaxel 5fludarabine 4durvalumab 4aldesleukin 4Immune Checkpoint Inhibitors 4Biopsy 4fludarabine phosphate 3Valproic Acid 3Radiation 3Interleukin-2 3Drug Therapy 3Bevacizumab 3130-nm albumin-bound paclitaxel 3tislelizumab 2sintilimab 2avelumab 2apatinib 2Tablets 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × tislelizumab × Head & Neck × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT04666688 2025-02-12

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

PureTech

Phase 1/2 Completed
44 enrolled
GastrointestinalGenitourinaryHead & Neck

Bile Duct Neoplasms, Carcinoma, Transitional Cell, Colonic Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡